EOI samples may not be collected from the same IV access as the drug was administered. cSamples will be taken as directed when drug-related adverse event, Grade 3/4 infusion reaction, or hypersensitivity reaction is confirmed. Abbreviations: C = Cycle; D = Day; EOI = end of infusion; EOT = end of treatment; FU = follow-up. Revised Protocol No.: 04 Date: 31-May-2019 118 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 9.5-4: Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226 (Parts D and E) Study Day of Sample Collection(Cycle = 4 weeks)EventTime (Relative to Start of BMS-986226 Infusion) Hour:MinBMS-986226 Blood SampleBMS-986226 Immunogenicity Sample Treatment Cycles Cycle 1 Day 1 (C1D1)Pre-dosea00:00 X X EOIb00:30 X C2D1 Pre-dose 00:00 X X C3D1 Pre-dose 00:00 X X C4D1 Pre-dose 00:00 X X C7D1 Pre-dose 00:00 X X Every 3 Cycles starting with C10D1 (example: C13D1, C16D1, etc)Pre-dose 0:00 X X Adverse Event Grade 3/4 Hypersensitivity ReactioncX End of Treatment and Follow-up Period EOT X X 30-Day FU X X 60-Day FU X X 100-Day FU X X Revised Protocol No.: 04 Date: 31-May-2019 119 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS aAll pre-dose samples for BMS-986226 should be taken prior to the start of nivolumab/ipilimu mab infusion (preferably within 30 minutes). bThis sample should be taken immediately prior to the stopping of the second drug infusion (in combination therapy), preferab ly within 2 minutes prior to the end of infusion.